1. Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab
- Author
-
Yingchun Xu, Zhan Zhou, Gaoqi Weng, Jiansheng Fan, Xiaoyue Yang, Ying Zhang, Xinlei Zhuang, Shuqing Chen, Liqiang Pan, Shanshan Wu, and Tingjun Hou
- Subjects
0301 basic medicine ,Mutation ,biology ,Somatic cell ,medicine.drug_class ,Drug resistance ,medicine.disease ,medicine.disease_cause ,Monoclonal antibody ,Metastasis ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,Trastuzumab ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,biology.protein ,Pharmacology (medical) ,Pertuzumab ,Antibody ,skin and connective tissue diseases ,neoplasms ,medicine.drug - Abstract
Background The aberrant expression of HER2 is highly associated with tumour occurrence and metastasis, therefore HER2 is extensively targeted for tumour immunotherapy. For example, trastuzumab and pertuzumab are FDA-approved monoclonal antibodies that target HER2-positive tumour cells. Despite their advances in clinical applications, emerging resistance to these two HER2-targeting antibodies has hindered their further application. Somatic mutations in HER2 receptor have been identified as one of the major reasons for resistance to anti-HER2 antibodies. Methods We analysed the frequency of somatic mutations in various tumour types based on TCGA and COSMIC databases. Then, the effect of the most frequent mutation (S310F) on the interaction between pertuzumab and HER2 was analysed by molecular modelling analysis. The effect of the S310F mutation was further evaluated through multiple in vitro binding experiments and antitumour activity assays. Results We found through bioinformatics analysis that S310F, an activating mutation in the HER2 extracellular domain, was the most frequent mutation in HER2. The S310F mutation was shown to confer resistance of HER2-positive tumour cells to pertuzumab treatment. With molecular modelling analysis, we confirmed the possibility that the S310F mutation might disrupt the interaction between pertuzumab and HER2 as a result of a significant change in the critical residue S310. Further functional analyses revealed that the S310F mutation completely abolished pertuzumab binding to HER2 receptor and inhibited pertuzumab antitumour efficacy. Conclusion We demonstrated the loss-of-function mechanism underlying pertuzumab resistance in HER2-positive tumour cells bearing the S310F mutation.
- Published
- 2019
- Full Text
- View/download PDF